A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer

Highlights • LY2603618 (LY) is a selective checkpoint kinase 1 inhibitor. • LY was added to standard first-line treatment for patients with nonsquamous NSCLC. • Primary endpoint of significantly improved PFS was met with addition of LY. • No statistically significant improvement in secondary efficac...

Full description

Saved in:
Bibliographic Details
Published inLung cancer (Amsterdam, Netherlands) Vol. 108; pp. 212 - 216
Main Authors Wehler, Thomas, Thomas, Michael, Schumann, Christian, Bosch-Barrera, Joaquim, Viñolas Segarra, Nuria, Dickgreber, Nicolas J, Dalhoff, Klaus, Sebastian, Martin, Corral Jaime, Jesus, Alonso, Miriam, Hynes, Scott M, Lin, Ji, Hurt, Karla, Bence Lin, Aimee, Calvo, Emiliano, Paz-Ares, Luis
Format Journal Article
LanguageEnglish
Published Ireland Elsevier B.V 01.06.2017
Subjects
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Checkpoint kinase 1
Checkpoint Kinase 1 - antagonists & inhibitors
Cisplatin
Cisplatin - administration & dosage
Disease Progression
Female
Hematology, Oncology and Palliative Medicine
Humans
Induction Chemotherapy
Kaplan-Meier Estimate
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Lung Neoplasms - pathology
LY2603618
Maintenance Chemotherapy
Male
Non-small cell lung cancer
Pemetrexed
Pemetrexed - administration & dosage
Phenylurea Compounds - administration & dosage
Pulmonary/Respiratory
Pyrazines - administration & dosage
Treatment Outcome
selective inhibitor of checkpoint kinase 1
LY + Pem + Cis
pemetrexed + cisplatin
CHK1
LY2603618 + pemetrexed + cisplatin
Checkpoint kinase 1
Non-small cell lung cancer
Pem + Cis
LY2603618
Pemetrexed
Cisplatin
LY+Pem+Cis
Pem+Cis
Online AccessGet full text

Cover

More Information
Summary:Highlights • LY2603618 (LY) is a selective checkpoint kinase 1 inhibitor. • LY was added to standard first-line treatment for patients with nonsquamous NSCLC. • Primary endpoint of significantly improved PFS was met with addition of LY. • No statistically significant improvement in secondary efficacy endpoints with LY. • There was a numerical increase in the rate of thromboembolic events with LY
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2017.03.001